Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pilot Study of BB3 to Improve Renal Function in Patients With Signs and Symptoms of Significant Renal Injury After Kidney Transplantation From Donors After Cardiac Death

Trial Profile

Pilot Study of BB3 to Improve Renal Function in Patients With Signs and Symptoms of Significant Renal Injury After Kidney Transplantation From Donors After Cardiac Death

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ANG 3777 (Primary)
  • Indications Delayed graft function; Renal failure
  • Focus Therapeutic Use
  • Sponsors Angion Biomedica
  • Most Recent Events

    • 07 Nov 2019 Results published in the Angion Biomedica Media Release.
    • 07 Nov 2019 According to an Angion Biomedica media release, data from this study presented as a late-breaking abstract at the American Society of Nephrology Kidney Week 2019 Annual Meeting (ASN19).
    • 18 Feb 2016 Planned End Date changed from 1 Dec 2015 to 1 May 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top